Navigation Links
Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Date:10/3/2007

onically infected with HCV genotype 1. This adaptive Phase 1 study is comprised of three parts:

Part 1 is a single ascending dose study of R7128 conducted in 46 healthy volunteers. The primary objective of Part 1 is to assess the safety, tolerability and pharmacokinetics of R7128 following single ascending doses under fasting conditions. The secondary objective of Part 1 is to explore the effect of food on the pharmacokinetics of R7128. Results from the single ascending dose portion of the study indicated that all doses of R7128 studied (500 mg to 9000 mg) were generally safe and well-tolerated. All patients completed the study, and none experienced gastrointestinal adverse events or serious adverse events during the study. No hematological or laboratory abnormalities of clinical significance were noted.

Part 2 is a multiple ascending dose study of R7128 conducted in 40 patients chronically-infected with HCV genotype 1 who previously failed interferon therapy. The primary objective of Part 2 is to assess the safety, tolerability and pharmacokinetics of R7128 after once-daily (QD) or twice- daily (BID) dosing for 14 days. The secondary objective is to assess antiviral activity by measuring the change in HCV RNA. Preliminary data from the multiple ascending dose portion of the study indicated that R7128 demonstrated potent, dose-dependent antiviral activity in four patient cohorts receiving 750 mg or 1500 mg administered either once-daily or twice-daily for 14 days as monotherapy. Patients receiving 1500 mg BID demonstrated a mean 2.7 log10 IU/mL (>99%) decrease in HCV RNA. There was no evidence of viral rebound in any dose cohort during the 14 days of dosing. R7128 was generally safe and well tolerated. There were no serious adverse events, no adverse events requiring dose modification, no dose-related gastrointestinal adverse events and no clinically significant changes in hematologic or other laboratory parameters.

Part 3 is a multi-center, observ
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... As health officials across the Midwest warn against the widespread ... Michigan will offer free diagnostic testing for ... to administer tests and, in some cases, fill the matching ... the study. The Grand Rapids, Mich. ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment of ... Executive Officer.  Mark was promoted from his current role of ... four facilities in Massachusetts , ... Medical in 2012 with 20+ years of broad-based operations, sales, ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Stryker Corporation (NYSE: SYK ) announced ... of Porex Corporation. Porex Surgical is a developer, manufacturer ... use primarily in reconstructive surgery of the head and ... market with strong brand recognition and considerable clinical data ...
... Pursuant to the provisions of Section 7 paragraph 1(a) ... Biedingen Wft) requiring a public announcement within four weeks following ... status update, Johnson & Johnson (NYSE: JNJ ) ... Swiss Exchange: CRX) provide the following joint update. ...
Cached Medicine Technology:Stryker Announces Acquisition of Privately-Held Porex Surgical 2Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer 2Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer 3Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer 4Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer 5
(Date:4/17/2014)... inflammation in benign prostate tissue was associated with ... was found even in those with low prostate-specific ... in Cancer Epidemiology, Biomarkers & Prevention , ... Research. , An analysis of prostate tissue biopsies ... of the Prostate Cancer Prevention Trial (PCPT) found ...
(Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
(Date:4/17/2014)... Biology and Medicine a multidisciplinary research team ... in the Institute of Genomic Biology (IGB) on ... describe their recent work on subcellular redox homeostasis. ... functions including energy metabolism, signaling, and transcriptional processes. ... cellular behavior, redox status has been recognized as ...
(Date:4/17/2014)... In a review published in the April issue ... of The Feinstein Institute for Medical Research, says it,s ... community,s approach to treating sepsis, which kills ... , Sepsis occurs when molecules released into the bloodstream ... the body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... military personnel who served in Iraq and Afghanistan ... injury (TBI) were compared to military personnel without ... Differences in measures of overall disability, cognitive function, ... are reported in an article in Journal ... Ann Liebert, Inc., publishers. The article is available ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2
... food and fluids during labour does not provide any ... University Associate Professor., "Based on our review, there is ... fluids, and perhaps food, for women during labour. ... Dr. Joan Tranmer of the Queen,s School of ...
... English-speaking Hispanic moms spend more time in front of ... News) -- Young children of Hispanic mothers whose main ... Hispanic moms who speak mostly English, a U.S. study ... 1,332 Hispanic and white mothers with children aged 4 ...
... ... system, Applicant Tracking System and Screening services. , ... Citrus Heights, CA (PRWEB) February 2, 2010 -- HR ... and efficient HRIS system, a web-based paperless Applicant Tracking System and an accurate, timely ...
... , MOUNT LAUREL, N.J. , Feb. 2 ... to announce the opportunity for individuals interested in voluntary service ... manager certification program in the United States . ... credential, CCMC is dedicated to upholding rigorous standards for its ...
... , Feb 2 The following news advisory was ...   Thirty-two Clear Channel stations nationwide will hold local radiothons ... , one of the world,s premier centers for the research and ... most organizations, St. Jude has not been immune to the effects ...
... might not be accurately diagnosed, Patients who do not have ... work, Calls for a briefer definition of the DSM-IV criteria ... led by Mark Zimmerman, MD, of Rhode Island Hospital indicates ... of psychiatrists reported that they often do not use the ...
Cached Medicine News:Health News:Spanish-Speaking Mothers Less Likely to Turn on TV 2Health News:HR Allen Provides Businesses with Three New Services. 2Health News:HR Allen Provides Businesses with Three New Services. 3Health News:CCMC Accepting Applications for Voluntary Service on its Board of Commissioners 2Health News:CCMC Accepting Applications for Voluntary Service on its Board of Commissioners 3Health News:32 Clear Channel Radio Stations Nationwide Unite to Fight Childhood Cancer February 11-12 2Health News:Study: Many physicians not using established criteria 2Health News:Study: Many physicians not using established criteria 3
Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle...
Ophthalmic surgery stretcher. Designed for exceptional surgeon access, ideal for either superior or temporal approach....
... Reliance mobile surgical stretcher. M-701 ... of 24 in. to 32 in., ... You may specify a high range, ... A 4 in. pad can be ...
... Visionblue is a staining solution for ... required for performing a safe phaco-emulsification ... lens capsule may result in an ... risk of radial capsule tears and ...
Medicine Products: